| 米氮平治疗躯体化障碍的疗效观察 |
| |
| 引用本文： | 叶敏捷,谢正,王瑛,郑维芳,姜德国. 米氮平治疗躯体化障碍的疗效观察[J]. 临床医学, 2006, 26(6): 14-15 |
| |
| 作者姓名： | 叶敏捷 谢正 王瑛 郑维芳 姜德国 |
| |
| 作者单位： | 浙江省温州市精神病院,温州,325005;河南省新乡医学院第二附属医院 |
| |
| 摘 要： | 目的观察米氮平对躯体化障碍的疗效和副反应。方法70例躯体化障碍患者随机分成米氮平苎碧垫娄藉萌虿，治疗8周，用症状自评量表（SCL-90）、临床疗效大体评定量表（CGI）评价疗效，用副反应量表（TESS）评价副反应。结果治疗8周后，米氮平和氯米帕明的疗效相当；米氮平比氯米帕明起效快，副反应较小。结论米氮平治疗躯体化障碍疗效确切、起效快、副反应小，可以作为躯体化障碍治疗的首选药物之一。
|
| 关 键 词： | 米氮平 躯体化障碍 氯米帕明 |
| 收稿时间： | 2006-02-01 |
| 修稿时间： | 2006-02-01 |
Mirtazapine in treatment of somatization disorder |
| |
| YE Minjie,XIE Zheng,WANG Ying,ZHENG Weifang,JIANG Deguo. Mirtazapine in treatment of somatization disorder[J]. Clinical Medicine, 2006, 26(6): 14-15 |
| |
| Authors: | YE Minjie XIE Zheng WANG Ying ZHENG Weifang JIANG Deguo |
| |
| Affiliation: | 1.Wenzhou Psychiatric Hospital, Wenzhou 325005, Zhejiang ; 2 . The Second Affiliated Hospital, Xinxiang Medical College ,Xinxiang 453000,Henan |
| |
| Abstract: | Objective To assess the efficacy and adverse effects of mirtazapine in treatment of somatization disorder.Methods Seventy patients with somatization disorder were randomly divided into two groups with mirtazapine or chlomipramine for 8 weeks.Symptom checklist 90(SCL-90) and clinical global impression(CGI) were used to assess the efficacy.Treatment emergent symptom scale(TESS) was used to assess adverse effects.Results After 8 weeks,mirtazapine and chlopramine had similar therapeutic efficacy,but mirtazapine showed efficacy earlier and had fewer adverse effects than chlompramine.Conclusion Mirtazapine is effective,it shows rapid effect and fewer adverse effects.We suggest that mirtazapine can be used as a primary treatment of somatization disorder. |
| |
| Keywords: | Mirtazapine Somatization disorder Chlomipramine |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
